Vaccine Development
& testing services
for high impact diseases

Advantages

Bringing Technology from Georgia Tech and the Scripps Research Institute to Industry

Accelerate Development

Our system can take your drug discovery timeline from years to months.

Click to learn more.

REDUCE COSTS

We can save most companies around 40% on testing their vaccine candidates. Our tests can confirm negative immunigenocity with a fraction of the trials used in current testing.

Flexibility

Services can be performed at our labs or in yours, or with approved CROs.

Tested Technology

NanoCliq’s technology has been vested by scientists at two of the world’s leading research institutions.

About

We can take two years off of your R&D timeline.

NanoCliq vaccine technology helps pharma companies to dramatically reduce R&D cost by shortening the testing required to identify high potential chemical entities, eliminating purification steps and bringing vaccines quickly to human clinical trials.

NanoCliq helps companies find vaccines up to ten times faster and at a fraction of the cost by using a novel new nanoparticle system developed at Georgia Tech.

  • % cost savings

    Using NanoCliq can save 40% or more off your testing budget.

  • % Time Savings

    NanoCliq can take 2 years off of your drug development timeline.

  • % Chance of Success

    The likelihood that partnering with NanoCliq will increase your odds of success.

OUR TEAM

Our international team of superstars, from MIT, Georgia Tech, Emory, Scripps, and Rice Universities
Uploaded image

MG Finn

Science Advisor
Uploaded image

Richard DiMonda

Business Advisor
Uploaded image

INDRA DATTA

CEO
Indra Datta holds Masters degrees in Computer Science from Rice University where he also worked in neuroscience research. He formerly founded and ran the medical data storage company MDVault.net.
Uploaded image

VIBIN ARAVINDAKSHAN

CFO and Operations
Uploaded image

Robert Demont

Chief Scientist
Uploaded image

NIKKI LEUNG

Business Development
Uploaded image

Bunny Sandefur

Intellectual Property

Focus Diseases

Latest news

Get in touch